Meyka Pro banner
Innovent Biologics, Inc.

Innovent Biologics, Inc. (1801.HK) Stock Competitors & Peer Comparison

See (1801.HK) competitors and their performances in Stock Market.

1801.HKHKSE
HealthcareBiotechnology
HK$91.65
HK$0.50(0.54%)
Hong Kong Market is Open · 14:21

Peer Comparison Table: Biotechnology Industry

Detailed financial metrics including price, market cap, P/E ratio, and more.

SymbolPriceChange %Market CapP/E RatioEPSDividend Yield
1801.HKHK$91.60-2.76%154.9B163.57HK$0.54N/A
4332.HKHK$1,850.00+0.00%998.5B45.81HK$40.38N/A
6160.HKHK$190.30-0.26%250.3B83.91HK$2.21N/A
2269.HKHK$37.90-3.61%153.2B28.94HK$1.28N/A
6990.HKHK$503.00-3.73%113.4B-241.15-HK$2.02N/A
9926.HKHK$92.50-9.14%81.3B-65.86-HK$1.34N/A
3347.HKHK$37.96-3.26%44.5B37.56HK$0.98+0.39%
6821.HKHK$119.20-7.38%42.3B38.43HK$3.05+1.28%
1530.HKHK$16.74-6.53%40.4B4.21HK$3.84+1.55%
2096.HKHK$12.93-1.52%32.4B21.28HK$0.59+1.64%
1

Stock Comparison

Select a stock to compare (requires JavaScript). Showing default comparison.

1801.HK vs 4332.HK Comparison July 2026

1801.HK plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, 1801.HK stands at 154.9B. In comparison, 4332.HK has a market cap of 998.5B. Regarding current trading prices, 1801.HK is priced at HK$91.60, while 4332.HK trades at HK$1,850.00.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

1801.HK currently has a P/E ratio of 163.57, whereas 4332.HK's P/E ratio is 45.81. In terms of profitability, 1801.HK's ROE is +0.05%, compared to 4332.HK's ROE of N/A. Regarding short-term risk, 1801.HK is more volatile compared to 4332.HK. This indicates potentially higher risk in terms of short-term price fluctuations for 1801.HK.Check 4332.HK's competition here

Stock price comparison of stocks in the Healthcare Sector

Loading...

Frequently Asked Questions